Previous close | 0.1000 |
Open | 0.1600 |
Bid | 0.0000 |
Ask | 0.3000 |
Strike | 7.50 |
Expiry date | 2024-06-21 |
Day's range | 0.1000 - 0.2500 |
Contract range | N/A |
Volume | |
Open interest | 5.3k |
Key Insights Significantly high institutional ownership implies Black Diamond Therapeutics' stock price is sensitive to...
Black Diamond Therapeutics (BDTX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Initial Phase 2 data of BDTX-1535 in 2L/3L EGFRm NSCLC patients on track for Q3 2024Enrollment ongoing in Phase 2 trial of BDTX-1535 in 1L patients with non-classical EGFRm NSCLC; initial data expected Q1 2025Presented real world evidence on the evolving EGFR mutation landscape in NSCLC, and the potential of BDTX-1535 across multiple lines of therapy at the 2024 AACR annual meetingPoster presentations upcoming June 1st at 2024 ASCO Annual Meeting on BDTX-1535 in GBM patients: Phase 1 dose-escala